Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive

CEActive

Will CE's combined H2 2026 (Q3 + Q4) adjusted EBITDA print below $1.0B?

Resolves February 28, 2027(239d)

IG: 0.60

Current Prediction

30%

Likely No

Model Agreement96%

Predictions9 runs

Last UpdatedApril 25, 2026

Why This Question Matters

H2 2026 adjusted EBITDA is the cyclical-recovery validation window. The committee anchored mid-cycle EBITDA at $2.5B implying H2 2026 should run at $900M-1.1B with cycle traction. A combined H2 below $1B indicates the cycle-extension scenario from Black Swan Beacon (10-15% probability with 50-70% drawdown) is materializing. A combined H2 at $1.1B+ would validate the recovery framing across stress-scanner, roadkill-radar, and myth-meter simultaneously. This market is the meta-check on whether the cycle thesis is operating in time for 2027 covenant compliance.

REVENUE_DURABILITYFUNDING_FRAGILITYEXPECTATIONS_PRICED

Prediction Distribution

0%25%50%75%100%

opus

sonnet

haiku

Range: 28% – 32%Aggregate: 30%

Individual Predictions(9 runs)

opusRun 1

30%

Mgmt FY2026 guide implies $1.7-1.9B EBITDA. H2 typically 55-58% of FY in chemicals = $935M-$1.10B at the low end of guide. Threshold $1.0B sits right at low-end-of-guide territory. Combined H2 below $1.0B requires either FY guide miss OR H2 weighting weaker than typical. Cycle-extension scenario (10-15%) maps to ~25-30% probability for this market when overlay seasonal/working-capital variability is added. ~30%.

Guide implies $935M-$1.10B H2Threshold at low-end-of-guideCycle-extension overlay

opusRun 2

28%

Mgmt narrative protection post-Citi rally creates incentive to deliver H2 in line. Cost-out program executing. EM pipeline 60-75% target — middle case. Tow contract reset uncertainty pulls probability slightly higher. Net ~28%.

Narrative protectionCost-out executionTow reset risk

opusRun 3

32%

Three risk factors compound: (1) auto/durables 2-year extension at 15-20% prob; (2) tow reset unfavorable at 30-40% prob; (3) EM pipeline shortfall at 25-30% prob. Conjunction (any two materializing) brings H2 EBITDA below $1.0B with moderate probability. Net ~32%.

Auto/durables extension riskTow resetEM pipeline shortfall

sonnetRun 1

32%

Threshold $1.0B is at the conservative end of guide-implied H2. Probability of H2 below this end ~30-35%. Cycle-extension scenario with 10-15% probability adds asymmetric downside. ~32%.

Conservative end of guideProbability distributionCycle-extension asymmetric

sonnetRun 2

30%

Base rate: chemicals trough years FY guides hit ~70% of time on H2 distribution. CE-specific: mgmt has executed FY guide reasonably in recent quarters. ~30%.

Sector base rateCE-specific executionRecent tracking

sonnetRun 3

30%

FY2026 guide $1.7-1.9B. H2 expectation $900M-$1.1B. $1.0B threshold central. Slight skew toward miss given cycle-extension tail. ~30%.

Central thresholdCycle-extension tailSkew direction

haikuRun 1

30%

Guide implies H2 ~$1.0B. Threshold central. Cycle extension overlay. ~30%.

Guide implicationCentral thresholdCycle extension

haikuRun 2

28%

Mgmt narrative protection. Cost-out execution. EM pipeline middle case. ~28%.

Narrative pressureCost-outEM pipeline

haikuRun 3

30%

Multiple risks compounding. Threshold near central case. ~30%.

Compounding risksCentral threshold

Resolution Criteria

Resolves YES if the sum of CE's reported Q3 2026 and Q4 2026 adjusted EBITDA (as defined in CE's earnings releases) is below $1.0B. Resolves NO if combined Q3+Q4 2026 adjusted EBITDA is at or above $1.0B.

Resolution Source

CE Q3 2026 and Q4 2026 earnings releases and 10-K FY2026 filing

Source Trigger

Adjusted EBITDA H2 2026 <$1B combined

stress-scannerREVENUE_DURABILITYHIGH

View CE Analysis

Full multi-lens equity analysis